Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Vanderbilt-Ingram Cancer Center
With
Primary Objectives To determine the safety and tolerability of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC. Secondary Objectives * To determine the anti-tumor effect of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC. * Pharmacokinetic assessments of erdafitinib Correlative Objectives * To determine the therapeutic predictive role of FGFR1-4, CCND1-2, CDK4 and CDK6 amplifications, and RB1 and ESR1 mutations on clinical outcome * To determine if the FGFR1 amplification levels is an early surrogate of response * To determine if the cfDNA results at disease progression show new genomic alterations potentially associated with resistance to CDK4/6 and FGFR inhibition * To determine pharmacodynamic biomarkers of FGFR inhibition
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted